238 related articles for article (PubMed ID: 28901637)
41. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
42.
Bashank N; Sharef S; Mohran TZ; Khalil M
EJNMMI Rep; 2024 Apr; 8(1):8. PubMed ID: 38748324
[TBL] [Abstract][Full Text] [Related]
43. [Utility and prognostic value of PET/CT, bone marrow biopsy and aspirate for detection of bone marrow involvement in diffuse large B-cell lymphoma].
Jiang XY; Zou DM; Zhang YQ; Wang Z; Zhang W; Zhou DB; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):663-667. PubMed ID: 36709151
[No Abstract] [Full Text] [Related]
44. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
45. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.
Hong J; Lee Y; Park Y; Kim SG; Hwang KH; Park SH; Jeong J; Kim KH; Ahn JY; Park S; Park J; Lee JH
Ann Hematol; 2012 May; 91(5):687-695. PubMed ID: 22008868
[TBL] [Abstract][Full Text] [Related]
46. PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients.
Chen S; Wang S; He K; Ma C; Fu H; Wang H
Eur Radiol; 2018 Jul; 28(7):2942-2950. PubMed ID: 29383519
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic accuracy of pelvic magnetic resonance imaging for the assessment of bone marrow involvement in diffuse large B-cell lymphoma.
Ke Q; Liao CC; Tan XH; Guo BP; Cen H; Li LQ
PLoS One; 2021; 16(5):e0252226. PubMed ID: 34043683
[TBL] [Abstract][Full Text] [Related]
48. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
[TBL] [Abstract][Full Text] [Related]
49. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
Pakos EE; Fotopoulos AD; Ioannidis JP
J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
[TBL] [Abstract][Full Text] [Related]
50. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
[TBL] [Abstract][Full Text] [Related]
51. Bone marrow trephine biopsy in Hodgkin's lymphoma. Comparison with PET-CT scan in 65 patients.
Lakhwani S; Cabello-García D; Allende-Riera A; Cárdenas-Negro C; Raya JM; Hernández-Garcia MT
Med Clin (Barc); 2018 Feb; 150(3):104-106. PubMed ID: 28864087
[TBL] [Abstract][Full Text] [Related]
52. CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT.
Bier G; Hoffmann V; Kloth C; Othman AE; Eigentler T; Garbe C; La Fougère C; Pfannenberg C; Nikolaou K; Klumpp B
Eur J Radiol; 2016 Apr; 85(4):732-8. PubMed ID: 26971416
[TBL] [Abstract][Full Text] [Related]
53. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
54. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
Jackson AE; Smeltzer JP; Habermann TM; Jones JM; Burnette B; Ristow K; Wiseman GA; Macon WR; Nowakowski GS; Witzig TE
Am J Hematol; 2014 Sep; 89(9):865-7. PubMed ID: 24823914
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of
Öner AO; Sürer Budak E; Aydın F; Salim O; Yücel OK; Akkaya B; Toptaş T; Boz A; Yıldız A; Güngör F; Undar L
Mol Imaging Radionucl Ther; 2017 Jun; 26(2):69-75. PubMed ID: 28613199
[TBL] [Abstract][Full Text] [Related]
56. The Diagnostic Accuracy of Bone Marrow Biopsy Versus PET/CT Scan in Identifying Bone Marrow Involvement in Diffuse Large B Cell Lymphoma Patients at a Cancer Hospital.
Asif H; Zubair R; Siddiqui IA; Tariq Mahmood M; Jamil A; Tahir A
Cureus; 2023 Feb; 15(2):e34901. PubMed ID: 36938170
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
[TBL] [Abstract][Full Text] [Related]
58. Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.
Jelicic J; Hansen DL; Carlsen SS; Thorsgaard M; Hersby DS; Kannik K; Munksgaard ASE; Larsen TS; Juul-Jensen K
Ann Hematol; 2023 Jul; 102(7):1897-1905. PubMed ID: 37246974
[TBL] [Abstract][Full Text] [Related]
59. Assessing bone marrow involvement in diffuse large B-cell lymphoma with 18F-FDG PET/CT: A preliminary experience at Hospital Pulau Pinang.
Siti Maisarah MN; Mahayuddin AM; Fadzilah H
Med J Malaysia; 2021 Sep; 76(5):665-671. PubMed ID: 34508372
[TBL] [Abstract][Full Text] [Related]
60. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study.
Ródenas-Quiñonero I; Chen-Liang T; Martín-Santos T; Salar A; Fernández-González M; Celades C; Navarro JT; Martínez-Garcia AB; Andreu R; Balaguer A; Martin García-Sancho A; Baile M; López-Jiménez J; Marquet-Palomanes J; Teruel AI; Terol MJ; Benet C; Frutos L; Navarro JL; Uña J; Suarez M; Cortes M; Contreras J; Ruiz C; Tamayo P; Mucientes J; Sopena-Novales P; Reguilón-Gallego L; Sánchez-Blanco JJ; Pérez-Ceballos E; Jerez A; Ortuño FJ
Cancer Med; 2023 Mar; 12(6):6536-6546. PubMed ID: 36373169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
